Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

13/11/2024 - 05:21

Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCC

Announced agreement with Roche to support advancement of amezalpat into first-line HCC pivotal Phase 3 trial

Received final funding approval from NCI to move TPST-1495 into a Phase 2 trial in FAP

Expanded leadership team to strengthen global clinical expertise